Immune checkpoint inhibitor-related enterocolitis (irEC)(Stage not disclosed)
Status note Most advanced LBP candidate. Phase 1b in allo-HCT complete; final Phase 2 protocol submitted to FDA Jan 2026; company paused additional investment pending funding for the Phase 2 study. IST in moderate-to-severe irEC ongoing.
SER-603
Stage not disclosed · ActiveModality: live biotherapeutic (oral bacterial consortium)
Indications
Inflammatory bowel disease (ulcerative colitis, Crohn's disease)(Stage not disclosed)
Status note Novel live biotherapeutic product (LBP) candidate; company exploring collaborations for I&I programs.
SER-428
Stage not disclosed · ActiveModality: live biotherapeutic (oral liquid formulation)
Partnerships CARB-X: grant of up to $3,583 (second CARB-X award) supporting development of oral liquid formulation based on SER-155 strains.
Indications
AMR infections in medically vulnerable patients (e.g., intubated ICU)(Stage not disclosed)
Status note Oral liquid formulation of SER-155 strains for patients who cannot take capsules. No trial stage stated.
SER-147
Stage not disclosed · ActiveModality: live biotherapeutic (oral bacterial consortium)
Status note Named among LBP candidates; no indication or stage stated in excerpts.
Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.